ERIBULINE ADVANZ PHARMA 0.44 mg/ml, solution for injection bottle, 2 ml
Active ingredients: Eribulin mesylate, Eribulin
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 2 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ERIBULINE ADVANZ PHARMA 0,44 mg/mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon en verre de 2 mL
- Marketing authorisation holder
- ADVANZ PHARMA LIMITED
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 19 Feb 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60267292CIP73027930CIP133400930279304Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ÉRIBULINEsolution | 0,44 mg · 1 mL de solution | FT |
| MÉSILATE D'ÉRIBULINEsolution | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.